Nov 6, 2020
A randomized, double-blind, placebo-controlled trial conducted to assess if early intervention with interleukin-6 receptor blockade might limit COVID-19 progression to hypoxemic respiratory failure or death, reduce the risk of clinical worsening, and decrease the duration of supplemental oxygen use.